Aptah Bio

This morning our CEO, Rafael M. Bottos, presented Aptah's rejuvenation technology called RNA WiCoTM (RNA Widespread Correction), able to restore overall RNA quality control on any given cell simultaneously. This technology will revolutionize how age-related diseases are treated by delivering the first, and so far the only compound to work as a genome-wide transcription modulator, correcting multiple mRNAs and toxic proteins at the same time. Our results successfully restored 30 years of RNA damage in just 7 days of treatment in human neurons. We are at the BIO Conference, in San Diego – USA, until June 6th – booth #4035. Come talk with us! #aptahbio #vesperventures #longevity #cancers #alzheimers #BIO2024

A recent article presents important evidence on gene-length-dependent transcription decline, a common event in the aging process and age-related diseases such as Alzheimer's and many kinds of cancer. Aptah’s lead compound successfully rescues the expression of longer genes and their integrity in human neurons and animal studies. source https://lnkd.in/dxNM_WtJ #aptahbio #alzheimers #longevity #aging

Yesterday, we had the great opportunity to meet Professor Alysson Muotri at the Sanford Consortium for Regenerative Medicine at UCSD in San Diego. Professor Muotri is a world-leading scientist in stem cell research and leads over 200 laboratories within UCSD. He conducts amazing studies related to the effects of microgravity on astronauts and the accelerated aging effect on their brains, which are funded by NASA - National Aeronautics and Space Administration NIH Clinical Center (CC) and other agencies. Aptah's technology could potentially be the solution to this challenge. Our effort to close a research collaboration with Prof. Muotri will be one of our priorities. We are eager to see what we could achieve together. #aptahbio #BIO2024 #longevity #bioinvestors

At Bio 2024, we are sharing important achievements of our novel rejuvenation technology. Beyond other important indications, we also shared important results for sporadic cancers, such as Glioblastoma Multiforme, the deadliest brain cancer, where we exceeded the gold standard treatment in vivo with a completely different mechanism of action. We are eager to start our first in human (Phase 0) studies next year. #aptahbio #bioinvestors #longevity #cancers #alzheimers

Today we joined the IX Summit Brazil at UCSD in San Diego. The event brought together the main biotechnology leaders in Brazil to share innovations, challenges and synergies. Directors of organizations such as ABIQUIFI, APEX, SINDUSFARMA, BNDES, ANVISA, MINISTRY OF HEALTH MCTI and BP&H were also at the event. We attended a presentation of Dr. Alysson Muotri, professor at UCSD and Vesper Ventures scientific advisor, on the effects of microgravity on astronaut biology. #aptahbio #vesperventures #bioinvestors #BIO2024

We are excited to share this short 3D animation on the basic concept of our lead compound. Our proprietary RNA rejuvenation technology targets U1 snRNP, a crucial element in all cells responsible for mRNA length and variety in all cells. Aptah developed the first, and so far, the only drug able to ensure U1 snRNP assembly,  restoring overall RNA integrity, the expression of multiple toxic proteins simultaneously, and the diseases they cause. #aptahbio #cancers #longevity #alzheimers https://lnkd.in/darcuUes

Join us at BIO 2024, June 3-6 in San Diego!  We are working with leading global scientists, laboratories, and the best patent attorneys to develop the next pharmaceutical blockbuster with a multi-billion dollar market value, able to impact the lives of millions of people. Aptah Bio is working in the forefront of a novel and proprietary rejuvenation technology called RNA WiCo (RNA Widespread Correction) able to edit, modulate and control the expression of different RNAs in a unique way. Its lead compound targets U1-snRNP and is the first drug designed to ensure the proper function of U1, leading to the expression of widespread full-length 3′UTRs. This directly contributes to the restoration of RNA integrity and the inclusion of non-coding RNA binding sites. We can't wait to connect with you to discuss how we're shaping the future of biotechnology. Find us at Booth 4035. See you there! https://lnkd.in/dKrXuHVa #aptahbio #vesperventures #alzheimers #longevity #cancers #BIO2024

About 90% of all diseases are sporadic, meaning they are not associated with inherited genetic mutations. However, their etiology remains a long-standing question for scientists. While many diseases share fundamental biological processes necessary for their development and progression, they also differ in their reliance on specific pathways. In recent years, targeted therapies have been introduced with varying degrees of success. However, single-targeted therapies may only be effective for certain types of diseases and may not address malignancies that rely on multiple pathways, a common aspect in sporadic diseases. Maintaining RNA integrity is crucial for healthy cells. Aging leads to an increasingly frequent and random loss of RNA integrity over time, resulting in overall RNA truncation, the production of harmful proteins, and the onset of age-related diseases. Recently, researchers have identified the sporadic occurrence of premature cleavage and polyadenylation, which leads to shorter 3′UTRs and a reduction in important binding sites for microRNAs. Data strongly suggests that widespread reductions in the 3′UTR-based regulatory capacity of mRNAs are closely linked to the development of multiple sporadic diseases. U1 snRNP, a guardian of mRNAs: Pre-mRNA splicing and polyadenylation are crucial steps in mRNA maturation. U1 snRNP, an essential component of the splicing machinery. Recent studies have shown that U1 snRNP also plays a global role in 3' end mRNA processing by preventing premature 3'-end cleavage and polyadenylation (PCPA), which is important for the full-length transcription of thousands of protein-coding and long noncoding genes. Numerous studies have demonstrated abnormalities in U1 snRNP assembly and function in various sporadic diseases, including neurodegenerative diseases and various types of cancer.  Aptah Bio is working in the forefront of a novel and proprietary rejuvenation technology called RNA WiCo (RNA Widespread Correction) able to edit, modulate and control the expression of different RNAs in a unique way. Its lead compound targets U1-snRNP and is the first drug designed to ensure the proper function of U1, leading to the expression of widespread full-length 3′UTRs. This directly contributes to the restoration of RNA integrity and the inclusion of non-coding RNA binding sites. #aptahbio #longevity #vesperventures #bioinvestors

About 80% of cancers are sporadic, meaning they are not associated with inherited genetic mutations. However, the cause of increased cell proliferation across different cell types and tissues remains a long-standing question for scientists. Cancer is a complex group of diverse diseases. While many cancers share fundamental biological processes necessary for their development and progression they also differ in their reliance on specific oncogenic pathways. In recent years, targeted therapies have been introduced with varying degrees of success. However, single-targeted therapies may only be effective for certain types of #cancer and may not address malignancies that rely on multiple pathways, a common aspect in sporadic diseases. Maintaining RNA integrity is crucial for healthy cells. Aging leads to an increasingly frequent and random loss of RNA integrity over time, resulting in overall RNA truncation, the production of harmful proteins, and the onset of age-related diseases. The stability, localization, and translation of messenger RNA (mRNA) are largely determined by sequences in the 3′ untranslated region (3′UTR). Recently, researchers have identified the sporadic occurrence of premature cleavage and polyadenylation, which leads to shorter 3′UTRs and a reduction in important binding sites for microRNAs. This phenomenon is a common characteristic of gene expression during immune cell activation and is associated with increased proliferation across different cell types and tissues. Data strongly suggests that widespread reductions in the 3′UTR-based regulatory capacity of mRNAs are closely linked to the development of multiple cancers. U1 snRNP, a guardian of RNA: If widespread RNA truncation is a common occurrence in sporadic cancers, what is driving the loss of RNA transcription integrity in so many cell types and tissues? Pre-mRNA splicing and polyadenylation are crucial steps in mRNA maturation. U1 snRNP, an essential component of the splicing machinery, is involved in splice-site selection and spliceosome assembly by base-pairing to the 5' splice site. Recent studies have shown that U1 snRNP also plays a global role in 3' end mRNA processing by preventing premature 3'-end cleavage and polyadenylation (PCPA), which is important for the full-length transcription of thousands of protein-coding and long noncoding genes. Numerous studies have demonstrated abnormalities in U1 snRNP assembly and function in various sporadic diseases, including #neurodegenerativediseases and various types of cancer.  Aptah's lead compound targets U1-snRNP and is the first drug designed to ensure the proper function of U1, leading to the expression of widespread full-length 3′UTRs. This directly contributes to the restoration of RNA integrity and the inclusion of non-coding RNA binding sites. Results have shown the restoration of homeostatic protein expression, cell cycle regulation, and positive biological effects in different cell types and animal models.

In San Diego from June 3th to 6th, our Head of preclinical research, Dr. Camila Guimarães Moreira Zimmer, PhD will represent Aptah Bio together with our CEO Rafael M. Bottos M. Bottos at the BIO Conference. Join us at BIO 2024 and let's discuss how we're shaping the future of biotechnology. Find us at Booth 4035. See you there! https://lnkd.in/dKrXuHVa #aptahbio #longevity #oncology #alzheimers #vesperventures #bio2024